Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475

• ClinicalTrials.gov Identifier: NCT02430363
• Recruitment Status: Unknown
• First Posted: April 30, 2015
• Last Update Posted: February 24, 2016
• Sponsor: Medical Research Council
• Collaborators: Department of Experimental Clinical Oncology, Aarhus University Hospital; NCRI Clinical Studies Groups; ECCO - the European CanCer Organisation; Merck Sharp & Dohme Corp.
• Information provided by (Responsible Party): Ms. Jann Lee, Medical Research Council

Study Description

Brief Summary:

It is known that after application of MK-3475 activated PD -1 negatively regulates the activation of T cells through suppression of the path of PI3K / Akt.

This study will identify the effectiveness of oral inhibitors of PI3K / Akt pathway in comparison with MK-3475 (pembrolizumab).

Condition or disease	Intervention/treatment	Phase
Glioblastoma	Drug: MK - 3475; Biological: Suppressor of the PI3K/Akt pathways	Phase 1; Phase 2

Detailed Description:

A humanized monoclonal IgG4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immunopotentiating activity. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include PD-L1, which is expressed on antigen presenting cells (APCs) and overexpressed on certain cancer cells, and PD-L2, which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation through the suppression of the PI3K/Akt pathway.

This study will identify the effectiveness of oral inhibitors of PI3K / Akt pathway in comparison with MK-3475 (pembrolizumab).

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 58 participants
• Allocation: Non-Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Phase IIb Trial Evaluations Of The Effectiveness Of Treatment Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475 (Pembrolizumab)
• Study Start Date: March 2013
• Actual Primary Completion Date: January 2016
• Estimated Study Completion Date: June 2018

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: MK-3475; Pembrolizumab (MK-3475) is a humanized monoclonal antibody. Information from these studies suggests that Pembrolizumab (MK-3475) may be beneficial in Glioblastoma / Gliosarcoma.; Patients enrolling in phase 1 receive MK-3475 every 3 weeks, with the dose to be determined.; MK-3475 will be given intravenously over the course of 30 minutes	Drug: MK - 3475; Administered Intravenously; Other Names: Pembrolizumab; Keytruda
Experimental: Suppressor of the PI3K/Akt pathways; Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ. Patients will take the Pictilisib (capsules) orally with food. The dose should be taken every 3 weeks. BEZ235 (NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor. Inhibits ATR whileshown to be a poor inhibitor to Akt and PDK1. Patients will take the BEZ235 (capsules) orally with food. The dose should be taken every 3 weeks. Ipatasertib (GDC-0068) is a highly selective pan-Akt inhibitor targeting Akt1/2/3 . Patients will take the Ipatasertib (capsules) orally with food. The dose should be taken every 3 weeks. The suggested dosage of inhibitors of the PI3K/Akt pathway orally as a single dose in capsule and Packed in plastic boxes, so that preparations can be taken at home	Biological: Suppressor of the PI3K/Akt pathways; Capsules orally with food; Other Names: Pictilisib; GDC-0941; BEZ235; NVP-BEZ235; Ipatasertib; GDC-0068

Outcome Measures

Primary Outcome Measures :

1. Progression Free Survival [ Time Frame: Time Frame: 12 months ]
   To evaluate the anti-tumor activity of pembrolizumab among subjects with recurrent glioblastoma when treated with pembrolizumab (Cohort A), and when treated with inhibitors PI3K/Akt pathways monotherapy (Cohort B) as assessed by the 12-month progression-free survival (PFS-12) rate.

Secondary Outcome Measures :

1. Safety and tolerability of Pembrolizumab (Assessed by reported adverse events using CTCAE version 4.0) [ Time Frame: Time Frame: 12 months ]
   Assesed by reported adverse events using CTCAE version 4.0. Progression Free Survival

Other Outcome Measures:

1. Safety and tolerability of inhibitors PI3K/Akt pathways as monotherapy (adverse events using CTCAE version 4.0) [ Time Frame: Time Frame: 12 months ]
   Assesed by reported adverse events using CTCAE version 4.0. Progression Free Survival

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Have histologically confirmed World Health Organization Grade IV malignant glioma (glioblastoma or gliosarcoma). Participants will be eligible if the original histology was low-grade glioma and a subsequent histological diagnosis of glioblastoma or variants is made.
• Previous first line therapy with at least radiotherapy and temozolomide
• Be at first or second relapse.
• Participants must have shown unequivocal evidence for tumor progression by MRI or CT scan.
• CT or MRI within 14 days prior to start of study drug.
• An interval of at least 4 weeks (to start of study agent) between prior surgical resection or one week for stereotactic biopsy.
• An interval of at least 12 weeks from the completion of radiation therapy to start of study drug unless there is a new area of enhancement consistent with recurrent tumor outside the radiation field or there is unequivocal histologic confirmation of tumor progression
• Participants must have recovered to grade 0 or 1 or pre-treatment baseline from clinically significant toxic effects of prior therapy (including but not limited to exceptions of alopecia, laboratory values listed per inclusion criteria, and lymphopenia which is common after therapy with temozolomide).
• From the projected start of scheduled study treatment, the following time periods must have elapsed: 5 half-lives from any investigational agent, 4 weeks from cytotoxic therapy (except 23 days for temozolomide and 6 weeks from nitrosoureas), 6 weeks from antibodies, or 4 weeks (or 5 half-lives, whichever is shorter) from other anti-tumor therapies.
• Payment of charitable contributions may be required

Exclusion Criteria:

• Current or planned participation in a study of an investigational agent or using an investigational device.
• Has a diagnosis of immunodeficiency.
• Has tumor primarily localized to the brainstem or spinal cord.
• Has presence of diffuse leptomeningeal disease or extracranial disease.
• Has received systemic immunosuppressive treatments within 6 months of start of study drug
• Requires treatment with high dose systemic corticosteroids defined as dexamethasone > 4 mg/day or bioequivalent for at least 3 consecutive days within 2 weeks of start of study drug.
• Has received prior interstitial brachytherapy, implanted chemotherapy, stereotactic radiosurgery or therapeutics delivered by local injection or convection enhanced delivery.
• Requires therapeutic anticoagulation with warfarin at baseline; patients must be off warfarin or warfarin-derivative anti-coagulants for at least 7 days prior to starting study drug; however, therapeutic or prophylactic therapy with low-molecular weight heparin is allowed.
• Has history of known coagulopathy that increases risk of bleeding or a history of clinically significant hemorrhage within 12 months of start of study drug
• Has evidence of intratumoral or peritumoral hemorrhage on baseline MRI scan other than those that are grade ≤ 1 and either post-operative or stable on at least 2 consecutive MRI scans.
• Has gastrointestinal bleeding or any other hemorrhage/bleeding event CTCAE Grade > 3 within 6 months of start of study drug.
• Has a known additional malignancy that is progressing or requires active treatment within 3 years of start of study drug. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy.
• Has an active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents.
• Has evidence of interstitial lung disease or active, non-infectious pneumonitis.
• Has an active infection requiring systemic therapy.
• Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
• Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
• Is pregnant or breastfeeding, or expecting to conceive within the projected duration of the trial
• Has a known history of HIV
• Has known active Hepatitis B or Hepatitis C
• Has received a live vaccine within 30 days prior to the first dose of study drug.
• Has a known hypersensitivity to any of the study therapy products.
• Has received anti-angiogenic or anti-VEGF targeted agents (e.g. bevacizumab, cediranib, aflibercept, vandetanib, XL-184, sunitinib, etc)
• Has a history of non-healing wounds or ulcers, or bone refractures within 3 months of fracture
• Has a history of arterial thromboembolism within 12 months of start of study drug.
• Has inadequately controlled hypertension
• Has a history of hypertensive crisis or hypertensive encephalopathy
• Has had clinically significant cardiovascular disease within 12 months of start of study drug
• Has a history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to start of study drug.

Contacts and Locations

Locations

United States, Massachusetts

Dana-Farber Cancer Institute

Boston, Massachusetts, United States, 02115

United States, Texas

M D Anderson Cancer Center

Houston, Texas, United States, 77030

Belgium

UCL- Cliniques Universitaires Saint Luc

Brussels, Belgium

Germany

St Johannes Hospital

Duisburg, Germany, 47166

Italy

Spedali Civili di Brescia

Brescia, Italy

IRCCS San Raffaele

Milan, Italy

Poland

Lower-Silesian Oncology Centre

Wroclaw, Lower-Silesian, Poland, 53413

Russian Federation

Pavlov State Medical University

St. Petersburg, Russian Federation, 197089

Spain

Hospital Universitario Germans Trias I Pujol

Barcelona,, Spain

Switzerland

Universitätsklinik für Frauenheilkunde

Bern, Switzerland

Ukraine

Regional Cancer Center

Dnepropetrovsk, Ukraine, 49000

National Institute of Cancer

Kiev, Ukraine, 03035

United Kingdom

Royal Victoria Hospital

Belfast, Ulster, United Kingdom, BT12 6BA

Sponsors and Collaborators

Medical Research Council

Department of Experimental Clinical Oncology, Aarhus University Hospital

NCRI Clinical Studies Groups

ECCO - the European CanCer Organisation

Merck Sharp & Dohme Corp.

Investigators

• Principal Investigator: Jann Lee, PhD; MRC Clinical Trials Unit

More Information

• Responsible Party: Ms. Jann Lee, PhD, Medical Research Council
• ClinicalTrials.gov Identifier: NCT02430363
• Other Study ID Numbers: ETIK-W/33-15
• First Posted: April 30, 2015
• Last Update Posted: February 24, 2016
• Last Verified: February 2016

Keywords provided by Ms. Jann Lee, Medical Research Council:

pembrolizumab; MK-3475; Glioblastoma; Gliosarcoma; Suppressor of the PI3K/Akt pathways; Pictilisib; GDC-0941; BEZ235; NVP-BEZ235; Ipatasertib; GDC-0068

Additional relevant MeSH terms:

Glioblastoma; Gliosarcoma; Astrocytoma; Glioma; Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue; Pembrolizumab; Dactolisib; Antineoplastic Agents, Immunological; Antineoplastic Agents